This is a preview of subscription content, log in via an institution to check access.
Notes
2015 British pounds
Reference
Lee D, et al. Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England. PharmacoEconomics-Open : 22 May 2018. Available from: URL: https://doi.org/10.1007/s41669-018-0080-5
Rights and permissions
About this article
Cite this article
Nivolumab plus ipilimumab cost effective for advanced melanoma. PharmacoEcon Outcomes News 804, 22 (2018). https://doi.org/10.1007/s40274-018-4986-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4986-z